GlassScriptPhysician profile
Danielle Nadiene Kwasnicka
NPI 1043759392
$506.31
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $118 · 2021: $138 · 2022: $83.67.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $122.62 | 2019 | |
| Abbvie INC. | $88.37 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $57.59 | 2020-2021 | |
| Novo Nordisk INC | $50.40 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $48.36 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.21 | 2021 | |
| Alexion Pharmaceuticals, INC. | $25.57 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $16.47 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.06 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.93 | 2019 | |
| Merck Sharp & Dohme LLC | $13.03 | 2021 | |
| Glaxosmithkline, LLC. | $12.70 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Kwasnicka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.